SCHEMBL5409507

SCHEMBL5409507

NC(Cc1ccccc1)(C(F)(F)F)C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.54
SLC6A2 P23975 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.48
HIF1A Q16665 1/20 0.48
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LOXL2 Q9Y4K0 2/20 0.40
LMNA P02545 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAOB P27338 3/20 0.39
MAOA P21397 2/20 0.39
CES1 P23141 2/20 0.39
FDPS P14324 1/20 0.38
CALM1 P0DP23 1/20 0.38
KIF11 P52732 2/20 0.37
CYP2A6 P11509 1/20 0.37
HTR2A P28223 1/20 0.37
TSHR P16473 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5408804 0.98 TAAR1 (0.52) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL5885752 0.80 TAAR1 (0.58) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL6112087 0.78 CES1 (0.41) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL5211703 0.77 SLC6A2 (0.48) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL10503241 0.76 TAAR1 (0.67) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL5402199 0.76 SLC6A2 (0.48) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL3248504 0.75 SLC6A2 (0.46) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL11021341 0.75 SLC6A2 (0.46) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL3277336 0.75 SLC6A2 (0.46) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2
SCHEMBL28615049 0.74 SLC6A2 (0.57) TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7247725-B2 Gamma-aminoamide modulators of chemokine receptor activity MERCK & CO., INC. (US) 2007-07-24 US disclosed
EP-1558250-A4 GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-20050261325-A1 Especially N-(3-carbonylamino3-substituted-propyl)spiro(indene- or indane-2,4'-piperidine derivatives, useful in treatment of inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, autoimmune disorders and atherosclerosis MERCK SHARP & DOHME CORP. 2005-11-24 US disclosed
EP-1558250-A1 GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2005-08-03 EP disclosed
WO-2004041279-A1 GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261325-A1 Especially N-(3-carbonylamino3-substituted-propyl)spiro(indene- or indane-2,4'-piperidine derivatives, useful in treatment of inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, autoimmune disorders and atherosclerosis CCR1, CCR3, CCR2 TAAR1 121/4885SLC6A2 4839/4885SMN1; SMN2 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.